Canis ISSN: 2398-2942

Masitinib

Synonym(s): Masivet

Contributor(s): Gerry Polton

Introduction

Name

  • Masitinib.

Class of drug

  • Protein-tyrosine kinase inhibitor.

Description

Chemical name

  • Masitinib.

Molecular formula

  • C28H30N6OS

Molecular weight

  • 498.64

Physical properties

  • Film-coated tablet.

Storage requirements

  • No special storage conditions required.

Uses

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Indications

  • Treatment of non-resectable canine mast cell tumors Skin: mastocytoma (Grade 2 or 3) withconfirmedmutation of the c-kit tyrosine kinase receptor.
  • For any mast cell tumor treatable by surgery, surgery should be the first choice of treatment.

Administration

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Pharmocokinetics

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Precautions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Interactions

with other drugs

  • Caution is advised with concurrent use of masitinib and other substances.
  • Concurrent use of other substances with a high degree of protein binding may compete with mastinib binding and thus cause adverse effects.
  • The efficacy of masitinib might be reduced in dogs previously treated with chemotherapy Mast cell tumor: chemotherapy protocols and/or radiotherapy Radiotherapy.

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Refereed papers

  • Recent references fromPubMed.
  • Hahn K A, Oglivie G, Rusk T, Devauchelle P, Leblanc A, Legendre A, Powers B, Leventhal P S, Kinet J P, Palmerini F, Dubreuil P, Moussy A, Hermine O (2008)Masitinib is safe and effective for the treatment of canine mast cell tumors.J Vet Int Med22(6), 1301-1309PubMed.

Other sources of information


ADDED